LuAG-09222 is under clinical development by H. Lundbeck and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LuAG-09222’s likelihood of approval (LoA) and phase transition for Grass Pollen Allergy took place on 31 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LuAG-09222 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LuAG-09222 overview

LuAG-09222 is under development for the treatment of grass pollen allergic rhiniti, chronic and frequent episodic migraine. It is administered through intravenous route. It is a monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38(PACAP-38). It is developed based on ABS(antibody selection) technology.

H. Lundbeck overview

H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, France, Italy, and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.

Quick View LuAG-09222 LOA Data

Report Segments
  • Innovator
Drug Name
  • LuAG-09222
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Immunology
Key Developers
  • Sponsor Company: H. Lundbeck
  • Originator: Lundbeck Seattle BioPharmaceuticals
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.